药品注册申请号:020726
申请类型:NDA (新药申请)
申请人:NOVARTIS PHARMS
申请人全名:NOVARTIS PHARMACEUTICALS CORP
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 FEMARA LETROZOLE TABLET;ORAL 2.5MG Yes Yes AB 1997/07/25 1997/07/25 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/12/16 SUPPL-43(补充) Approval Labeling STANDARD
2018/04/05 SUPPL-35(补充) Approval Labeling STANDARD
2017/07/13 SUPPL-33(补充) Approval Labeling STANDARD
2016/10/28 SUPPL-30(补充) Approval Manufacturing (CMC) STANDARD
2015/12/23 SUPPL-29(补充) Approval Manufacturing (CMC) STANDARD
2014/01/15 SUPPL-27(补充) Approval Labeling STANDARD
2013/07/11 SUPPL-25(补充) Approval Manufacturing (CMC) STANDARD
2011/12/23 SUPPL-24(补充) Approval Labeling UNKNOWN
2010/06/25 SUPPL-19(补充) Approval Labeling STANDARD
2010/04/30 SUPPL-20(补充) Approval Efficacy STANDARD
2010/03/02 SUPPL-16(补充) Approval Efficacy UNKNOWN
2010/03/02 SUPPL-15(补充) Approval Efficacy UNKNOWN
2009/07/07 SUPPL-18(补充) Approval Labeling STANDARD
2008/08/07 SUPPL-17(补充) Approval Labeling STANDARD
2007/04/11 SUPPL-14(补充) Approval Labeling STANDARD
2006/06/26 SUPPL-13(补充) Approval Labeling STANDARD
2005/12/28 SUPPL-12(补充) Approval Efficacy PRIORITY
2004/10/29 SUPPL-11(补充) Approval Efficacy UNKNOWN
2003/02/26 SUPPL-5(补充) Approval Efficacy STANDARD
2003/01/17 SUPPL-8(补充) Approval Efficacy STANDARD
2002/01/10 SUPPL-7(补充) Approval Manufacturing (CMC) STANDARD
2001/02/05 SUPPL-3(补充) Approval Manufacturing (CMC) STANDARD
2001/01/10 SUPPL-6(补充) Approval Efficacy PRIORITY
2000/05/23 SUPPL-4(补充) Approval Manufacturing (CMC) STANDARD
1999/04/22 SUPPL-2(补充) Approval Manufacturing (CMC) STANDARD
1999/03/17 SUPPL-1(补充) Approval Manufacturing (CMC) STANDARD
1997/07/25 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 4978672 2011/06/03 U-203 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 I-446 2007/10/29**本条是由Drugfuture回溯的历史信息**
I-481 2008/12/28**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:LETROZOLE 剂型/给药途径:TABLET;ORAL 规格:2.5MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
020726 001 NDA FEMARA LETROZOLE TABLET;ORAL 2.5MG Prescription Yes Yes AB 1997/07/25 NOVARTIS PHARMS
090289 001 ANDA LETROZOLE LETROZOLE TABLET;ORAL 2.5MG Prescription No No AB 2011/06/03 TEVA PHARMS
090934 001 ANDA LETROZOLE LETROZOLE TABLET;ORAL 2.5MG Prescription No No AB 2011/06/03 ACCORD HLTHCARE
091191 001 ANDA LETROZOLE LETROZOLE TABLET;ORAL 2.5MG Prescription No No AB 2011/06/03 RYAN LABS
200161 001 ANDA LETROZOLE LETROZOLE TABLET;ORAL 2.5MG Prescription No No AB 2011/06/03 NATCO PHARMA LTD
201804 001 ANDA LETROZOLE LETROZOLE TABLET;ORAL 2.5MG Discontinued No No AB 2011/06/03 INDICUS PHARMA
205869 001 ANDA LETROZOLE LETROZOLE TABLET;ORAL 2.5MG Prescription No No AB 2018/11/14 BEIJING YILING
211717 001 ANDA LETROZOLE LETROZOLE TABLET;ORAL 2.5MG Prescription No No AB 2019/01/11 EUGIA PHARMA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database